LENZ Therapeutics, Inc. (NasdaqGS: LENZ)
Health Care · Pharmaceuticals · US
$4.68
+0.43% today · -88.3% 1Y
LENZ Therapeutics, Inc. (NasdaqGS: LENZ) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $147.05M and employs 152 people.
Over the last twelve months the share price has lost 88.3%, trading between 4.54 and 50.40.
Tweenvest scores LENZ Therapeutics, Inc. across four factors: quality 34/100, value 40/100. Its strongest factor is value.
LENZ price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $147.05M
- Revenue (TTM)
- $21.48M
- P/E
- —
- EPS
- -4.12
- Dividend yield
- —
- Beta (5Y)
- 1.63
- 52-week high
- $50.40
- 52-week low
- $4.54
- Avg volume (3M)
- —
- Shares outstanding
- 31.42M
- Employees
- 152
- Next earnings
- —
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
- Founded
- 2013
- Listed since
- Jun 25, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.